Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy

S. P. Chawla, S. Pollack, M. Block, M. Druta, K. Do, J. C. Morris, J. W. Kim, C. Bohac, H. Lu, S. Gnjatic, R. L. Jones, P. Hwu, N. Somaiah

Research output: Contribution to journalArticle

8 Scopus citations
Original languageEnglish (US)
Pages (from-to)viii578
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Chawla, S. P., Pollack, S., Block, M., Druta, M., Do, K., Morris, J. C., Kim, J. W., Bohac, C., Lu, H., Gnjatic, S., Jones, R. L., Hwu, P., & Somaiah, N. (2018). Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii578. https://doi.org/10.1093/annonc/mdy299.006